RSS
TwitterFacebook

Taxotere Lawsuits

columns_sky_ss_133333943

Contact A Lawyer

Have A Potential Case Reviewed By An Attorney

  • This field is for validation purposes and should be left unchanged.

Side effects of the breast cancer drug Taxotere may cause some women to suffer permanent baldness or hair loss, known as alopecia. Lawsuits are being pursued against the drug maker for failing to adequately warn about this potential risk.

ABOUT TAXOTERE LAWSUITS: Product liability lawyers are reviewing potential claims for women nationwide who may be entitled to financial compensation through a Taxotere hair loss lawsuit, alleging that information about the risk of permanent baldness should have been provided by the drug maker, since treatment alternatives were available.

MANUFACTURER: Sanofi-Aventis

>>CONTACT A TAXOTERE LAWYER ABOUT A CASE<<

OVERVIEW: Taxotere (docetaxel) is a breast cancer drug sold by Sanofi-Aventis, which was approved by the FDA in May 1996 for treatment of patients with locally advanced or metastatic breast cancer after prior chemotherapy attempts had failed, competing with several other treatment alternatives. The drug is administered as an injection given with other chemotherapy drugs.

Although information has been available to the drug maker for years to suggest a link between side effects of Taxotere and permanent baldness, warnings provided with the medication indicate that “hair generally grows back” and fails to disclose information about the large number of reports involving women who have experienced permanent hair loss.

A number of similar cancer treatments are on the market, which may be just as effective at Taxotere, but do not pose a risk of long-term or permanent alopecia for women.

Failure to warn about the Taxotere hairloss risks deprived women and medical providers of the opportunity to make an informed decision about whether the benefits provided by the drug justify the potential for permanent baldness.

TAXOTERE HAIR LOSS SIDE EFFECTS: While many cancer drugs cause hair loss, it appears that Sanofi-Aventis knew or should have known that use of their treatment carried a high risk of permanent baldness or alopecia. Rather than providing warnings and information, lawsuits allege that the drug maker has concealed this information.

In 2005, a study known as GEICAM 9805 found that 9.2% of patients who took Taxotere experienced long-term hair loss for up to 10 years and five months, and in some cases longer. This study was sponsored by Sanofi-Aventis, and the drug maker knew or should have been aware of the results for years before it was concluded.

Reports of Taxotere hair loss problems were also submitted to the drug maker by medical providers. In 2006, at least one Denver-based oncologist reported that 6.3% of patients he treated with Taxotere suffered permanent hair loss for years after taking the drug.

Alopecia problems from Taxotere are disfiguring and cause severe psychological damage, mental anguish, economic losses and an overall impact on a woman’s quality of life.

Failure to warn about the Taxotere balding side effects that may persist for years or permanently deprived women and the medical community of the ability to decide for themselves whether the risks were justified in comparison to alternative treatments.

To review whether you or a loved one may be eligible to pursue a Taxotere settlement for permanent hair loss, request a free case evaluation.


1 comment

  1. jeffery Reply

    was diagnosed with testicular cancer in 96 at 18 and after it spread i was treated for the next 4-5 years. I was cured and then had a setback and after all was done my hair never grew back. I am now 38 and have struggled for many years trying to get my hair back.

  • Share Your Comments

  • Have Your Comments Reviewed by a Lawyer

    Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.
  • NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

  • This field is for validation purposes and should be left unchanged.